Vulvovaginal Candidiasis Treatment Market is Likely to Witness Steady Growth, anticipated to Reach US$ 1607 Million by 2033: Future Market Insights, Inc.
17 janv. 2023 00h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The global Vulvovaginal Candidiasis Treatment Market is currently valued at US$ 1035 Million in 2023 and is anticipated to expand at a CAGR of 4.5%....
Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC
21 févr. 2017 07h30 HE
|
Cidara Therapeutics, Inc.
Further Development of CD101 Topical for VVC to be discontinued CD101 IV development program in candidemia and invasive candidiasis (including Phase 2 STRIVE trial) continuing and remains on track ...
Cidara Therapeutics and Square 1 Bank Announce $20 Million Credit Facility
02 nov. 2016 07h30 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other...
Cidara Therapeutics Announces Commencement of Public Offering of Common Stock
06 oct. 2016 16h01 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has...
Cidara Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
20 sept. 2016 16h05 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other...
Cidara Therapeutics to Present at the Cantor Fitzgerald Annual Healthcare Conference
06 juil. 2016 07h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, July 06, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other...
Cidara Therapeutics Expands Management Team
05 juil. 2016 07h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, July 05, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other...
Cidara Reports First Quarter 2016 Financial Results and Provides Corporate Update
12 mai 2016 17h12 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 12, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other...
Cidara Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
18 mars 2016 07h30 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, March 18, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other...
Cidara Therapeutics Announces Positive Data From Phase 1 Clinical Trial of CD101 IV and Reports Third Quarter 2015 Financial Results
16 nov. 2015 16h13 HE
|
Cidara Therapeutics, Inc.
-- Single Ascending Dose Study-Results Demonstrate Excellent Safety and Tolerability and Support Once-Weekly IV Dosing --
-- Management to Host Webcast and Conference Call Tomorrow at 8:00 a.m. ET...